Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Capital Expenditures (2019 - 2025)

C4 Therapeutics' Capital Expenditures history spans 7 years, with the latest figure at $582000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 14650.0% year-over-year to $582000.0; the TTM value through Dec 2025 reached $589000.0, up 227.22%, while the annual FY2025 figure was $607000.0, 237.22% up from the prior year.
  • Capital Expenditures reached $582000.0 in Q4 2025 per CCCC's latest filing, up from -$160000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.3 million in Q3 2022 to a low of -$1.5 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $407733.3, with a median of $171000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: crashed 202.89% in 2023, then skyrocketed 14650.0% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at -$421000.0 in 2021, then surged by 453.92% to $1.5 million in 2022, then plummeted by 202.89% to -$1.5 million in 2023, then skyrocketed by 99.74% to -$4000.0 in 2024, then surged by 14650.0% to $582000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Capital Expenditures are $582000.0 (Q4 2025), -$160000.0 (Q3 2025), and -$4000.0 (Q4 2024).